Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Safety and efficacy of apixaban versus low-molecular weight heparin or vitamin-K antagonists for venous thromboembolism treatment in patients with severe renal failure: A systematic review and meta-analysis

Published:2023-09 Issue: Volume:229 Page:77-85
ISSN:0049-3848
Container-title:Thrombosis Research
language:en
Short-container-title:Thrombosis Research

Author:

Almajdi Anwar,Almutairi Sara,Alharbi Maha

Publisher

Elsevier BV

Subject

Hematology

Reference37 articles.

1. Venous thrombosis;Wolberg;Nat Rev Dis Primers.,2015

2. The epidemiology of venous thromboembolism in the community: implications for prevention and management;Heit;J. Thromb. Thrombolysis,2016

3. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases;Jager;Kidney Int.,2019

4. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms;Wattanakit;Curr. Opin. Pulm. Med.,2009

5. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification;Levey;Am. J. Kidney Dis.,2002

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients;International Journal of Molecular Sciences;2024-08-09

2. Antiphospholipid Antibodies Associated with Native Arteriovenous Fistula Complications in Hemodialysis Patients: A Comprehensive Review of the Literature;Antibodies;2024-01-02

3. Apixaban reduces the risk of major and clinically relevant non-major bleeding compared to warfarin in patients with end stage renal disease; a systematic review and meta-analysis of ten studies;Thrombosis Research;2023-11